Release Date: September 12, 2025
Expiration Date: September 12, 2026
Activity Overview
Prostate cancer continues to pose substantial clinical challenges with increasing incidence and mortality rates in the United States. Radioligand therapy (RLT) directed at prostate-specific membrane antigen (PSMA) have transformed the diagnosis and treatment of metastatic prostate cancer, but knowledge gaps persist regarding optimal use, patient selection, sequencing, and integration into multidisciplinary care. Additionally, disparities in access and implementation across care settings underscore the urgent need for clinician education. To address these unmet needs, PER® has developed this online activity that features expert video interviews.
Target Audience
This activity is directed toward medical oncologists, urologists, and radiation oncologists.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate PSMA-directed radioligand therapy in the management of patients with mCRPC based on guideline recommendations and clinical trial evidence
- Develop best practices for identification and management of treatment-related toxicities in patients with mCRPC being treated with PSMA-directed radioligand therapy